Journal
MOLECULAR THERAPY
Volume 29, Issue 8, Pages 2469-2482Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2021.04.027
Keywords
-
Categories
Funding
- State of New Jersey Commission on Spinal Cord Research [15IRG006]
- Rutgers TechAdvance Fund
- U.S. Department of Education GAANN Precision and Personalized Medicine Pre-Doctoral Training Fellowship
- NIH Biotechnology Pre-Doctoral Training Fellowship [T32GM008339]
- New Jersey Commission on Spinal CordResearch Graduate Fellowship [CSCR12FEL001]
- NSF [CHE-1429062]
- NIH [R01 1R01DC016612]
Ask authors/readers for more resources
The study demonstrates that lentivirus-mediated expression of Gsx1 increases the number of NSPCs in a mouse model of spinal cord injury during the acute stage, promoting neuronal generation, reducing glial scar formation, and improving motor function in injured mice. Gsx1 gene therapy shows potential for functional recovery in spinal cord injuries and other parts of the central nervous system.
Promoting residential cells, particularly endogenous neural stem and progenitor cells (NSPCs), for tissue regeneration represents a potential strategy for the treatment of spinal cord injury (SCI). However, adult NSPCs differentiate mainly into glial cells and contribute to glial scar formation at the site of injury. Gsx1 is known to regulate the generation of excitatory and inhibitory interneurons during embryonic development of the spinal cord. In this study, we show that lentivirus-mediated expression of Gsx1 increases the number of NSPCs in a mouse model of lateral hemisection SCI during the acute stage. Subsequently, Gsx1 expression increases the generation of glutamatergic and cholinergic interneurons and decreases the generation of GABAergic interneurons in the chronic stage of SCI. Importantly, Gsx1 reduces reactive astrogliosis and glial scar formation, promotes serotonin (5-HT) neuronal activity, and improves the locomotor function of the injured mice. Moreover, RNA sequencing (RNA-seq) analysis reveals that Gsx1-induced transcriptome regulation correlates with NSPC signaling, NSPC activation, neuronal differentiation, and inhibition of astrogliosis and scar formation. Collectively, our study provides molecular insights for Gsx1-mediated functional recovery and identifies the potential of Gsx1 gene therapy for injuries in the spinal cord and possibly other parts of the central nervous system.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available